Beone Medicines Ltd. (Nasdaq: ONC) is one of the best international growing international shares to buy now. On September 9, the analyst of citizens JMP, Reni Benjamin, reiterated a purchase note on Beone Medicines Ltd. (Nasdaq: ONC) and set a price target of $ 348.00.
On August 29, Beone Medicines Ltd. (NASDAQ: ONC) announced the results of the Sonrotoclax positive line line in cell lymphoma in relapse or refractory mantle (MCL), declaring that the study satisfied its main point of evaluation of the overall response rate (orr) and presented clinically significant responses in the B-C-C-Cellume B.
Management added that Beone Medicines Ltd. (Nasdaq: ONC) would submit data to the global regulatory authorities for their examination and potential approval.
Home in Switzerland, Beone Medicines Ltd. (NASDAQ: ONC) is a global oncology company that discovers and develops affordable, accessible and innovative treatments for cancer patients.
Although we recognize the potential of the ONC as an investment, we believe that certain AI actions offer greater rising potential and have a less unknown risk. If you are looking for an extremely undervalued AI stock that should also benefit considerably from the Trump era tariffs and the excessive trend, see our free report on the Best short -term AI stock.
Read then: 30 actions that should double in 3 years And 11 Hidden AI stocks to buy now.
Disclosure: None. This article is initially published at Initiate monkey.
